AMERICAN ACADEMY OF NEUROLOGY

January 30, 2012

The US Food and Drug Administration (FDA) has provided the public with information regarding the drug natalizumab (Tysabri), which is commonly prescribed for treatment of relapsing forms of multiple sclerosis. In specific, on January 20, 2012, the FDA issued a drug safety communication regarding a new risk factor for progressive multifocal leukoencephalopathy (PML) associated with natalizumab. For more information on this communication, visit http://www.fda.gov/Drugs/DrugSafety/ucm288186.htm.

For general information about the FDA warnings concerning natalizumab, visit http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107198.htm.

To access the AAN's guideline titled "Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review)," visit http://www.neurology.org/content/71/10/766.full.pdf.

To access tools the AAN created relative to this guideline, visit www.aan.com/guidelines and search under "Multiple Sclerosis."